Lipigon: Comment on Q4 2025 - Redeye

Redeye comments on Lipigon’s Q4 report 2025. In Q4, Lipigon presented inconclusive results in its phase II study of Lipisense. Additional analyses have shown positive effects on glucose and ApoB-48. The cash runway is now likely a few more months and we believe the company needs a partner to survive.

Länk till analysen i sin helhet: https://www.redeye.se/research/1158471/lipigon-comment-on-q4-2025?utm_source=finwire&utm_medium=RSS